Malaysia secures Pfizer Covid-19 vaccine in a first for Southeast Asia

Final trial data showed that Pfizer's vaccine is 95% effective

Malaysia has agreed to buy 12.8 million doses of Pfizer's COVID-19 vaccine, becoming the first country in Southeast Asia to announce a deal with the U.S. drugmaker after some expressed reservations over the need for ultra-cold storage.

While final trial data showed that Pfizer's vaccine is 95% effective, many Asian countries are not betting on it partly due to tropical heat, remote island communities and a lack of ultra-cold freezers.

Pfizer's vaccine, jointly developed with German partner BioNTech, must be stored and transported at minus 70 degrees Celsius (-94F), although it can be kept in a fridge for up to five days, or up to 15 days in a thermal shipping box.

Prime Minister Muhyiddin Yassin said on Friday that Malaysia would prioritise "high-risk groups... including frontliners, senior citizens, and those with non-communicable diseases, such as heart diseases and diabetes".

Pfizer will deliver the first one million doses in the first quarter of 2021, with 1.7 million, 5.8 million and 4.3 million doses to follow in subsequent quarters.

The deal is expected to cover 6.4 million Malaysians, or 20% of the population, with another 10% to be covered under Malaysia's participation in the global COVAX facility, backed by the World Health Organization.

Malaysia, which will distribute the vaccine to its people for free, reported 1,109 new COVID-19 infections on Friday.

The country is also planning to run a Phase 3 trial of an experimental vaccine developed by the Chinese Academy of Medical Sciences. The trial will involve 3,000 participants.

Pfizer's vaccine still requires approvals from regulators including the U.S. Food and Drug Administration (FDA) and Malaysia's Health Ministry before it can be distributed, Muhyiddin said during a televised address.

The FDA plans a meeting on Dec. 10 to discuss whether to authorise the Pfizer vaccine for emergency use.

Pfizer and BioNTech have supply deals with several countries including the United States, Germany, Japan, Canada, Australia and Britain.

They expect to produce globally up to 50 million doses of vaccines in 2020 and up to 1.3 billion doses in 2021.

More than 150 potential vaccines are being developed and tested globally to stop the COVID-19 pandemic, with 48 in human trials, the WHO says.

This week AstraZeneca said its vaccine developed by Oxford University could be around 90% effective, following positive results from Pfizer, Moderna Inc and Russia's Sputnik V.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel